Huadong Medicine Subsidiary Receives Approval for Skin Treatment Device V30

Stock News06-24

Huadong Medicine Co.,Ltd. (SHE: 000963) has announced that its wholly-owned subsidiary, Viora Ltd., has obtained the Medical Device Registration Certificate from China's National Medical Products Administration (NMPA) for its Class III medical device, the skin treatment system V30. The approval was granted on June 24, 2026.

The V30 device, developed by Viora, is an integrated skin treatment platform combining radiofrequency (RF), intense pulsed light (IPL), and Nd:YAG laser energy sources. It incorporates proprietary technologies, including CORE™ bipolar RF and PCR™ IPL, and can be equipped with various specialized handpieces for IPL, RF, and laser treatments. The system is designed to offer customizable treatment regimens tailored to different skin types and concerns, providing comprehensive solutions for the face, neck, and body. Its applications include reducing wrinkles, hair removal, and treating vascular and pigmented lesions, as well as acne.

The V-Series products are noted for their strong compatibility, allowing for integration with new technologies Viora may develop in the future. The V30 model has previously received registration approvals from the U.S. Food and Drug Administration (FDA) and the European Union's CE marking. Another product in the same series, the V20 (branded as Renotion in English), received NMPA approval for market launch in September 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103413408?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 18:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103413408","market":"sh","top_or_hot":-1,"title":"Huadong Medicine Subsidiary Receives Approval for Skin Treatment Device V30","media":"Stock News","content":"<p><br><br>\n<b>Huadong Medicine Co.,Ltd.</b> (<b>SHE: 000963</b>) has announced that its wholly-owned subsidiary, Viora Ltd., has obtained the Medical Device Registration Certificate from China's National Medical Products Administration (NMPA) for its Class III medical device, the skin treatment system V30. The approval was granted on June 24, 2026.<br><br>\nThe V30 device, developed by Viora, is an integrated skin treatment platform combining radiofrequency (RF), intense pulsed light (IPL), and Nd:YAG laser energy sources. It incorporates proprietary technologies, including CORE™ bipolar RF and PCR™ IPL, and can be equipped with various specialized handpieces for IPL, RF, and laser treatments. The system is designed to offer customizable treatment regimens tailored to different skin types and concerns, providing comprehensive solutions for the face, neck, and body. Its applications include reducing wrinkles, hair removal, and treating vascular and pigmented lesions, as well as acne.<br><br>\nThe V-Series products are noted for their strong compatibility, allowing for integration with new technologies Viora may develop in the future. The V30 model has previously received registration approvals from the U.S. Food and Drug Administration (FDA) and the European Union's CE marking. Another product in the same series, the V20 (branded as Renotion in English), received NMPA approval for market launch in September 2024.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huadong Medicine Subsidiary Receives Approval for Skin Treatment Device V30</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuadong Medicine Subsidiary Receives Approval for Skin Treatment Device V30\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-24 18:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><br><br>\n<b>Huadong Medicine Co.,Ltd.</b> (<b>SHE: 000963</b>) has announced that its wholly-owned subsidiary, Viora Ltd., has obtained the Medical Device Registration Certificate from China's National Medical Products Administration (NMPA) for its Class III medical device, the skin treatment system V30. The approval was granted on June 24, 2026.<br><br>\nThe V30 device, developed by Viora, is an integrated skin treatment platform combining radiofrequency (RF), intense pulsed light (IPL), and Nd:YAG laser energy sources. It incorporates proprietary technologies, including CORE™ bipolar RF and PCR™ IPL, and can be equipped with various specialized handpieces for IPL, RF, and laser treatments. The system is designed to offer customizable treatment regimens tailored to different skin types and concerns, providing comprehensive solutions for the face, neck, and body. Its applications include reducing wrinkles, hair removal, and treating vascular and pigmented lesions, as well as acne.<br><br>\nThe V-Series products are noted for their strong compatibility, allowing for integration with new technologies Viora may develop in the future. The V30 model has previously received registration approvals from the U.S. Food and Drug Administration (FDA) and the European Union's CE marking. Another product in the same series, the V20 (branded as Renotion in English), received NMPA approval for market launch in September 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2328871848.SGD","symbol_name":"Eastspring Investments - China A Shares Growth AS SGD","start_time":0,"source_url":"","article_id":"1103413408","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103413408","pubTimestamp":1782298464,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":" Huadong Medicine Co.,Ltd. (SHE: 000963) has announced that its wholly-owned subsidiary, Viora Ltd., has obtained the Medical Device Registration Certificate from China's National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0187":"一线龙头","000963":"华东医药","BK0196":"行业龙头","BK0132":"高送转概念","BK0183":"MSCI概念","BK0209":"零售","BK0188":"融资融券","IPOS":"Renaissance International IPO ETF","BK0175":"白马股"},"translate_title":"华东医药子公司皮肤治疗器械V30获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000963":1,"IPOS":1},"content_text":"Huadong Medicine Co.,Ltd. (SHE: 000963) has announced that its wholly-owned subsidiary, Viora Ltd., has obtained the Medical Device Registration Certificate from China's National Medical Products Administration (NMPA) for its Class III medical device, the skin treatment system V30. The approval was granted on June 24, 2026.\nThe V30 device, developed by Viora, is an integrated skin treatment platform combining radiofrequency (RF), intense pulsed light (IPL), and Nd:YAG laser energy sources. It incorporates proprietary technologies, including CORE™ bipolar RF and PCR™ IPL, and can be equipped with various specialized handpieces for IPL, RF, and laser treatments. The system is designed to offer customizable treatment regimens tailored to different skin types and concerns, providing comprehensive solutions for the face, neck, and body. Its applications include reducing wrinkles, hair removal, and treating vascular and pigmented lesions, as well as acne.\nThe V-Series products are noted for their strong compatibility, allowing for integration with new technologies Viora may develop in the future. The V30 model has previously received registration approvals from the U.S. Food and Drug Administration (FDA) and the European Union's CE marking. Another product in the same series, the V20 (branded as Renotion in English), received NMPA approval for market launch in September 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103413408","isCrawlerRequest":true}